このレポートでは、イギリスのがん診断市場の動向を調査しています。現在および新たなアッセイのレビュー、新しい診断技術の潜在的な応用の分析、国および市場セグメントごとに主要な腫瘍マーカーの売上高の予測、主要なプレーヤーと潜在的な市場参入者のプロフィールの紹介、サプライヤーにとっての具体的なビジネスチャンスの特定を可能にします。
研究者らが腫瘍の診断と治療における大きな技術的進歩に近づき、新たな特異抗原を発見し、病気の遺伝的基盤の謎を解明するにつれて、がん診断市場は爆発寸前となっています。今後 5 年間で、世界のがん診断市場は刺激的でダイナミックかつ急速に拡大する分野になることが予想されます。予想される技術的進歩により、遺伝的素因の決定、特定の腫瘍の検出、がん治療に対する生物学的反応のモニタリングのための多くの機会が生み出されるでしょう。高齢者人口の増加は、悪性腫瘍検査に対する需要の高まりと世界中での急速な市場の拡大をさらに複雑にするでしょう。
目次
Table of Contents
I. Introduction
II. Worldwide Market Overview
III. Major Product Development Opportunities
A. Reagent Kits and Test Systems/Panels
B. Instrumentation
C. Computers, Software and Automation
D. Auxiliary Products
IV. Design Criteria for Decentralized Testing Products
V. Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies
VI. Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
VII. Worldwide Market and Technology Overview
A. Cancer Statistics and Etiology
1. Breast Cancer
2. Lung Cancer
3. Colon and Rectum Cancer
4. Prostate Cancer
5. Stomach Cancer
6. Leukemia
7. Lymphoma
8. Oral Cancer
9. Skin Cancer
10. Uterine Cancer
11. Ovarian Cancer
12. Bladder Cancer
B. Major Current and Emerging Cancer Diagnostic Tests
1. Introduction
2. Tumor Marker Classification
3. ACTH
4. Alpha-Fetoprotein (AFP)
5. Beta-2 Microglobulin
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. Calcitonin
10. Carcinoembrionic Antigen (CEA)
11. Estrogen and Progesterone Receptors
12. Ferritin
13. Gastrin
14. Human Chorionic Gonadotropin (HCG)
15. Insulin
16. NSE
17. Occult Blood
18. PAP Smear/HPV
19. Prostatic Acid Phosphatase (PAP)
20. Prostate-Specific Antigen (PSA)
21. Squamous Cell Carcinoma Antigen (SCC)
22. T and B Lymphocytes
23. TdT
24. Thyroglobulin
25. Tissue Polypeptide Antigen (TPA)
26. Biochemical Tumor Markers
27. Oncogenes
- Abl/abl-bcr
- AIB1
- BCL-2
- BRCA1
- CD44
- C-fos
- C-myb
- C-myc
- CYP-17
- Erb-B
- HPC1
- N-myc
- P40
- P51
- P53
- PIK3CA
- PTI-1
- Ras
- Reg
- Sis
- Src and others
28. Polypeptide Growth Factors
- Basic Fibroblast Growth Factor
- Beta-TGF
- Cachectin (TNT)
- Calmodulin
- ECFR
- Nerve Growth Factor (NGF)
- Epidermal Growth Factor (EGF)
- Ornithine Decarboxylase
- Transferrin
- Transforming Growth Factor-Alpha
29. Ectopic Hormones
30. Colony Stimulating Factors
31. Lymphokines
- Alpha-Interferon
- B Cell Growth Factors
- B Cell Growth Factor (BCGF)
- Gamma-Interferon
- Interleukin-1 (IL-1)
- Macrophage Activating Factor
32. Immunohistochemical Stains
33. Emerging Tumor Markers
- N-Acetylglucosamine
- Actin
- Alpha-Actin
- Antineuronal Antibodies
- 7B2
- B72.3
- Bax
- BCD-F9
- BLCA-4
- Blood Group Antigens A,B,H
- CA 50
- CA 72-4/TAG-72
- CA 195
- CA-242
- CA-549
- CAM 26
- CAR-3
- Cathepsin-D
- Chromogranin A and B
- Cluster 1 Antigen
- Cluster-5/5A Antigen
- CTA
- CU18
- DR-70
- DU-PAN-2
- Endometrial Bleeding Associated Factor
- Endostatin
- Epithelial Membrane Antigen
- Feulgen Hydrolysis
- Fibronectin
- FSH
- (1->3)-L-fucosyltransferase
- Gastrin-Releasing Peptide (GRP)
- GDCFP-15
- Glucagon
- Glycoamines
- H23
- Her-2
- Human Carcinoma Antigen
- HPA
- HSP27
- Intermediate Filaments
- Cytokeratins/CK18/Cyfra 21-1
- Desmin
- Gliofibrillary Acid Protein
- Neurofilaments
- Vimentin
- KA 93
- Kinases
- KP16D3
- LAI
- Leukocyte Common Antigen
- Lewis Antigens
- Lysophosphatidic Acid (LPA)
- Ma 695/Ma 552
- MABDF3
- MAG
- ME1
- Minactivin
- MN/CA9
- MSA
- Mucin Cancer Antigen (MCA)
- Multiple Tumor Suppressor 1
- Myosin
- NEA-130
- NMP22
- OA-519
- Opioid Peptides
- P-glycoprotein
- Pancreatic Oncofetal Antigen (POA)
- Placental Lactogen
- PR92
- Proliferative Index, Ki-67
- Px
- RB Inactivation/Deletion
- Ret
- SCCL 175
- Selectin
- Sialic Acid
- Sialyl SSEA-1/SLX
- SN10
- Somatostatin
- TA-90
- TABA
- Tachykinin
- TAG 12
- TPS
- Troponin
- Tubulin
- VCAM
- VEGF
- Villen and others
C. Cancer Diagnostic Testing Instrumentation Review and Market Needs
D. Current and Emerging Cancer Diagnostic Technologies
1. Monoclonal and Polyclonal Antibodies
2. Immunoassays
3. Molecular Diagnostics
4. Chromosome Analysis
a. Chronic Myelogenous Leukemia (CML)
b. Acute Myeloid Leukemia (AML)
c. Acute Lymphoblastic Leukemia (ALL)
d. Malignant Lymphomas Lymphoid Malignancies
e. Chronic Lymphocytic Leukemia (CLL)
f. Solid Cancers
g. Chromosomal Translocation and Oncogenes
5. Artificial Intelligence
6. Flow Cytometry
7. Two Dimensional Gel Electrophoresis (2-DGE)
8. Biosensors
9. Competing/Complementing Technologies
E. Personal Testing
VIII. Country Analysis
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Dynamics, Trends, Size and Growth
- Volume Forecasts by Test and Market Segment
- Sales Forecasts by Test and Market Segment
- Major Supplier Sales and Market Shares
IX. Competitive Profiles
The report provides strategic assessments of over 30 leading cancer diagnostics market players and start-up companies with innovative technologies and products, including:
- Abbott
- Affymetrix
- Beckman Coulter/Danaher/Cepheid
- Becton Dickinson
- bioMerieux
- Bio-Rad
- DiaSorin
- Eiken Chemical
- Elitech Group
- Enzo Biochem
- Fujifilm Wako
- Fujirebio
- Grifols
- Hologic
- Leica Biosystems
- PerkinElmer
- Qiagen
- QuidelOrtho
- Roche
- Siemens Healthineers
- Takara Bio
- Thermo Fisher and others
List of Tables
Tumor Marker Classification
Major Companies Developing or Marketing
ACTH Tests
Major Companies Developing or Marketing
AFP Tests
Major Companies Developing or Marketing
Beta-2 Microglobulin Tests
Major Companies Developing or Marketing
CA 15-3/27.29 Tests
Major Companies Developing or Marketing
CA 19-9 Tests
Major Companies Developing or Marketing
CA 125 Tests
Major Companies Developing or Marketing
Calcitonin Tests
Major Companies Developing or Marketing
CEA Tests
Major Companies Developing or Marketing
Estrogen Receptor Tests
Major Companies Developing or Marketing
Progesterone Receptor Tests
Major Companies Developing or Marketing
Ferritin Tests
Major Companies Developing or Marketing
Gastrin Tests
List of Tables
Major Companies Developing or Marketing
HCG Tests
Major Companies Developing or Marketing
Insulin Tests
Major Companies Developing or Marketing
NSE Tests
Major Companies Developing or Marketing
Occult Blood Tests
Major Companies Developing or Marketing
PAP Smear/HPV Tests
Major Companies Developing or Marketing
PAP Tests
Major Companies Developing or Marketing
PSA Tests
Major Companies Developing or Marketing
Lymphocyte Subclassification Tests
Biochemical Markers Potential Applications
In Cancer Diagnosis
Oncogenes Potential Applications
In Cancer Diagnosis
Major Companies Developing or Marketing
Oncogene Tests
Growth Factors Potential Applications
In Cancer Diagnosis
Colony Stimulating Factors Potential
Applications in Cancer Diagnosis
Lymphokines Potential Applications In Cancer Diagnosis
Immunohistochemical Stains Potential
Applications in Cancer Diagnosis
Executive Summary Table: U.K., Total
Tumor Marker Test Volume and Sales
Forecast by Market Segment
U.K., Laboratories Performing Tumor
Marker Tests by Market Segment
U.K., Hospital Laboratories Performing
Tumor Marker Tests by Bed Size
U.K., Commercial/Private Laboratories
Performing Tumor Marker Tests by Annual
Test Volume
U.K., Total Tumor Marker Testing Volume
Forecast by Market Segment
U.K., All Market Segments Major
Tumor Marker Test Volume Forecast
U.K., Hospital Laboratories Major Tumor
Marker Test Volume Forecast by Test
U.K., Commercial/Private Laboratories
Major Tumor Marker Test Volume Forecast
U.K., Total Tumor Marker Sales
Forecast by Market Segment
U.K., All Market Segments Major
Tumor Marker Sales Forecast by Test
U.K., Hospital Laboratories Major
Tumor Marker Sales Forecast by Test
U.K., Commercial/Private Laboratories
Major Tumor Marker Sales Forecast by Test
U.K., Total Tumor Marker Sales and Market Shares Forecast
U.K., CEA Testing Market Diagnostics
Sales by Major Supplier
U.K., PSA Testing Market Diagnostics
Sales by Major Supplier
